BET inhibition as a new strategy for the treatment of gastric cancer
Metrics: PDF 1036 views | HTML 1391 views | ?
Raquel C. Montenegro1,2,4, Peter G.K. Clark3, Alison Howarth2, Xiao Wan6, Alessandro Ceroni2, Paulina Siejka1,2, Graciela A. Nunez-Alonso1,2, Octovia Monteiro1,2, Catherine Rogers1,2, Vicki Gamble1,2, Rommel Burbano4, Paul E. Brennan1,2, Cynthia Tallant1,2, Daniel Ebner2, Oleg Fedorov1,2, Eric O’Neill6, Stefan Knapp1,2,5, Darren Dixon3, Susanne Müller1,2
1The Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7DQ, UK
2Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Headington, Oxford OX3 7FZ, UK
3Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, UK
4Federal University of Pará, Institute of Biological Sciences, Belém, Pará 66075-110, Brazil
5Institute for Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, Frankfurt am Main D-60438, Germany
6CRUK/MRC Oxford Institute of Radiation Biology, University of Oxford, Headington OX3 7DQ, UK
Raquel C. Montenegro, email: email@example.com
Susanne Müller, email: firstname.lastname@example.org
Keywords: epigenetic, bromodomain, BET inhibitors, cytotoxicity, gastric cancer
Received: December 11, 2015 Accepted: May 04, 2016 Published: June 01, 2016
Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to the development and progression of this malignancy. In order to explore new treatment options in this target area we have screened a library of epigenetic inhibitors against gastric cancer cell lines and identified inhibitors for the BET family of bromodomains as potent inhibitors of gastric cancer cell proliferations. Here we show that both the pan-BET inhibitor (+)-JQ1 as well as a newly developed specific isoxazole inhibitor, PNZ5, showed potent inhibition of gastric cancer cell growth. Intriguingly, we found differences in the antiproliferative response between gastric cancer cells tested derived from Brazilian patients as compared to those from Asian patients, the latter being largely resistant to BET inhibition. As BET inhibitors are entering clinical trials these findings provide the first starting point for future therapies targeting gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.